<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several actin-binding proteins have been shown to be altered in metastatic cell lines and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and, in particular, Myristoylated Alanine-Rich protein Kinase C substrate (MARCKS) has been implicated in the pathogenesis of various highly metastatic epithelial <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Considering that a large percentage of <z:hpo ids='HP_0011420'>deaths</z:hpo> due to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are consequent to hepatic metastasization, aim of this study was to elucidate the involvement and mechanism of MARCKS in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> by employing in vitro and in vivo approaches </plain></SENT>
<SENT sid="2" pm="."><plain>Loss-of and-gain-on function approaches of MARCKS were employed in two human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines: Clone A cells expressing MARCKS and LoVo cells known to have a frameshift mutation of MARCKS i.e. typically for MSI-H <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The data unveiled that altering MARCKS expression suppresses cell motility and invasion in human colon <z:mp ids='MP_0002038'>carcinoma</z:mp> cells when conditioned medium of liver-specific stromal cells (hepatic stellate cells) was used as chemoattractant </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_63'>Depletion</z:mpath> or re-expression of MARCKS inhibited proliferation with a reduction in expression of the mitotic regulator Aurora B kinase (AURKB), whereas AURKB-<z:mpath ids='MPATH_63'>depletion</z:mpath> did not modify MARCKS expression </plain></SENT>
<SENT sid="5" pm="."><plain>In murine colon <z:mp ids='MP_0002038'>carcinoma</z:mp> CT26 cells, shRNA MARCKS-<z:mpath ids='MPATH_63'>depletion</z:mpath> reduced motility and invasion, and induced an aberrant, prolonged mitotic process </plain></SENT>
<SENT sid="6" pm="."><plain>Significantly less <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> were produced in a syngeneic model of colon <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> by MARCKS-depleted CT26 in comparison to CT26-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> challenged mice </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, MARCKS plays an articulated role in the progression of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and might represent a suitable target to interfere and overcome the invasive behaviour of colon <z:mp ids='MP_0002038'>carcinoma</z:mp> cells at primary and distant sites </plain></SENT>
</text></document>